



Express Mail No. EV 456 934 061 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Chen et al. Confirmation No.: 4030
Serial No.: 10/705,173 Art Unit: 1625
Filed: November 6, 2003 Examiner: Aulakh, Charanjit
For: FUSED HETEROCYCLIC Attorney Docket No: 11134-013-999
COMPOUNDS

FEE TRANSMITTAL SHEET

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$0.00.


The claim amendment fee has been estimated as shown below:

(Col. 1)		(Col. 2)	(Col. 3)	<input type="checkbox"/> SMALL ENTITY		<input checked="" type="checkbox"/> OTHER THAN A SMALL ENTITY		
CLAIMS REMAINING AFTER AMENDMENT	MINUS	HIGHEST NO. PREVIOUSLY PAID	PRESENT EXTRA	RATE	ADDIT. FEE	OR	RATE	ADDIT. FEE
TOTAL	89	MINUS	102	0	x 25	\$	x 50	\$ 0.00
INDEP.	2	MINUS	3	0	x 100	\$	x 200	\$ 0.00
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					\$		\$	0.00
				TOTAL	\$	OR	TOTAL	\$ 0.00

Please charge the required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed.

Respectfully submitted,

Date: December 15, 2006


Roger C. Rich 54,398
(Reg. No.)
For: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

Enclosure



12-18-06

Express Mail No. EV 456 934 061 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Chen <i>et al.</i>	Confirmation No.:	4030
Serial No.:	10/705,173	Art Unit:	1625
Filed:	November 6, 2003	Examiner:	Aulakh, Charanjit
For:	FUSED HETEROCYCLIC COMPOUNDS	Attorney Docket No:	11134-013-999

RESPONSE UNDER 37 C.F.R. § 1.111

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The enclosed Response is in reply to the non-final Office Action dated August 10, 2006, for the above identified patent application. Enclosed herewith are a **Petition for Extension of Time** and an **Information Disclosure Statement**.

This paper includes the following:

Amendments to the Claims beginning on page 2; and

Remarks beginning on page 10.